UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

The New England journal of medicine, 1999-01, Vol.340 (4), p.253-259

1999

Volltextzugriff (PDF)

Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis

Annals of the rheumatic diseases, 2008-03, Vol.67 (3), p.346-352

2008

Volltextzugriff (PDF)

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial

Annals of internal medicine, 1999-03, Vol.130 (6), p.478

1999

Volltextzugriff (PDF)

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

The New England journal of medicine, 1997-07, Vol.337 (3), p.141-147

1997

Volltextzugriff (PDF)

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

Annals of the rheumatic diseases, 2006-08, Vol.65 (8), p.1006-1012

2006

Volltextzugriff (PDF)

Addressing the safety of anakinra in patients with rheumatoid arthritis

British journal of rheumatology, 2003-05, Vol.42 (suppl-2), p.ii29-ii35

Fleischmann, R M

2003

Volltextzugriff (PDF)

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

The New England journal of medicine, 2000-11, Vol.343 (22), p.1586-1593

2000

Volltextzugriff (PDF)

Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis

Arthritis and rheumatism, 2009-11, Vol.60 (11), p.3225-3228

Fleischmann, R. M.

2009

Volltextzugriff (PDF)

Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial

Current medical research and opinion, 2005-08, Vol.21 (8), p.1181-1190

2005

Volltextzugriff (PDF)

SAT0117 Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of The IL-6 Receptor: Relationship Between Eular Responses and Change from Baseline of Selected Clinical Parameters

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A620-A620

2013

Volltextzugriff (PDF)

Early diagnosis and treatment of rheumatoid arthritis for improved outcomes: Focus on etanercept, a new biologic response modifier

Clinical therapeutics, 1999-09, Vol.21 (9), p.1429-1442

Fleischmann, Roy M.

1999

Volltextzugriff (PDF)

SAT0006 No Differences in Patient-Reported Outcomes by Methotrexate Dose Among Early Rheumatoid Arthritis Patients Treated Concomitantly with Adalimumab: Results from the Concerto Trial

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A580-A581

2013

Volltextzugriff (PDF)

THU0239 Methotrexate Dose has Minimal Effects on Methotrexate-Related Toxicity in Patients with Early Rheumatoid Arthritis Treated in Combination with Adalimumab – Results of Concerto Trial

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A246-A246

2013

Volltextzugriff (PDF)

SAT0131 Long-Term Safety of Rituximab: Pooled Analysis of the Rheumatoid Arthritis Global Clinical Trial Programme Over 11 Years

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A625-A626

2013

Volltextzugriff (PDF)

FRI0178 Five-year safety and efficacy of golimumab in methotrexate-naïve patients with rheumatoid arthritis: final study results of the phase 3, randomized, placebo-controlled go-before trial

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A432-A432

2013

Volltextzugriff (PDF)

POS0645 LONG-TERM SAFETY AND EFFICACY OF OLOKIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS – RESULT OF AN OPEN-LABEL EXTENSION STUDY, CREDO4

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.593-593

2022

Volltextzugriff (PDF)

AB0352 IMPACT OF SEROLOGIC STATUS ON CLINICAL RESPONSES TO UPADACITINIB OR ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO BIOLOGIC DMARDs: SUB-GROUP ANALYSIS FROM THE PHASE 3 SELECT-CHOICE STUDY

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.1302-1303

2022

Volltextzugriff (PDF)

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

Journal of rheumatology, 2015-10, Vol.42 (10), p.1761-1766

2015

Volltextzugriff (PDF)

POS0640 OLOKIZUMAB IMPROVED PATIENT REPORTED OUTCOMES IN MTX AND TNF INCOMPLETE RESPONDER RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE LONG TERM EXTENTION TRIAL

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.596-597

2023

Volltextzugriff (PDF)

AB0333 SUSTAINABILITY OF RESPONSE TO UPADACITINIB AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.1290-1291

2022

Volltextzugriff (PDF)

Treatment of rheumatoid arthritis with a DR4/1 peptide

Journal of rheumatology, 2000-08, Vol.27 (8), p.1855

2000

Volltextzugriff (PDF)

OP0295 A 12-WEEK, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2B STUDY OF SAFETY, TOLERABILITY AND EFFICACY OF AR882 IN GOUT PATIENTS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.192-192

2023

Volltextzugriff (PDF)

POS0849 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: 5-YEAR DATA FROM THE SELECT-COMPARE STUDY

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.725-726

2023

Volltextzugriff (PDF)

POS0683 EFFICACY AND SAFETY OF UPADACITINIB IN TNFi-IR PATIENTS WITH RHEUMATOID ARTHRITIS FROM THREE PHASE 3 CLINICAL TRIALS

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.618-619

2022

Volltextzugriff (PDF)

POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.835-836

2022

Volltextzugriff (PDF)

1 – 25 von 1.112

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(909)
Mit Volltextzugriff
(908)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

Addressing the safety of anakinra in patients with rheumatoid arthritis

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis

Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial

SAT0117 Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of The IL-6 Receptor: Relationship Between Eular Responses and Change from Baseline of Selected Clinical Parameters

Early diagnosis and treatment of rheumatoid arthritis for improved outcomes: Focus on etanercept, a new biologic response modifier

SAT0006 No Differences in Patient-Reported Outcomes by Methotrexate Dose Among Early Rheumatoid Arthritis Patients Treated Concomitantly with Adalimumab: Results from the Concerto Trial

THU0239 Methotrexate Dose has Minimal Effects on Methotrexate-Related Toxicity in Patients with Early Rheumatoid Arthritis Treated in Combination with Adalimumab – Results of Concerto Trial

SAT0131 Long-Term Safety of Rituximab: Pooled Analysis of the Rheumatoid Arthritis Global Clinical Trial Programme Over 11 Years

FRI0178 Five-year safety and efficacy of golimumab in methotrexate-naïve patients with rheumatoid arthritis: final study results of the phase 3, randomized, placebo-controlled go-before trial

POS0645 LONG-TERM SAFETY AND EFFICACY OF OLOKIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS – RESULT OF AN OPEN-LABEL EXTENSION STUDY, CREDO4

AB0352 IMPACT OF SEROLOGIC STATUS ON CLINICAL RESPONSES TO UPADACITINIB OR ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO BIOLOGIC DMARDs: SUB-GROUP ANALYSIS FROM THE PHASE 3 SELECT-CHOICE STUDY

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

POS0640 OLOKIZUMAB IMPROVED PATIENT REPORTED OUTCOMES IN MTX AND TNF INCOMPLETE RESPONDER RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE LONG TERM EXTENTION TRIAL

AB0333 SUSTAINABILITY OF RESPONSE TO UPADACITINIB AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS

Treatment of rheumatoid arthritis with a DR4/1 peptide

OP0295 A 12-WEEK, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2B STUDY OF SAFETY, TOLERABILITY AND EFFICACY OF AR882 IN GOUT PATIENTS

POS0849 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: 5-YEAR DATA FROM THE SELECT-COMPARE STUDY

POS0683 EFFICACY AND SAFETY OF UPADACITINIB IN TNFi-IR PATIENTS WITH RHEUMATOID ARTHRITIS FROM THREE PHASE 3 CLINICAL TRIALS

POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS

Suchergebnisse filtern